Although disease activity returned after 6 months postpartum regardless of breast-feeding, this beneficial practice need not preclude optimal control of MS.
Can women with multiple sclerosis (MS) safely breast-feed? In an observational study of 466 pregnancies among 375 women with MS within Kaiser Permanente in California between 2008 and 2016, researchers examined disease characteristics, relapse rates, disability, breast-feeding, formula-feeding, and introduction of solid foods. Disease-modifying therapy (DMT) had been discontinued for at least 1 year prior to pregnancy in 48% of the women, 26% conceived while receiving a DMT, and only 3% were using a highly effective DMT. Overall likelihood of relapse declined during pregnancy then returned to prepregnancy levels by 4 to 6 months postpartum. During the year following pregnancy, relapses occurred in 26% of women.
Within the first 6 months post…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)